PD-1/PD-L1抑制剂致骨髓抑制不良反应文献分析  

A Quantitative Analysis of the Literature on Bone Marrow Suppression Induced by PD-1/PD-L1 Drugs

作　　者：刘欣 吴楠[1] 王玥[2] LIU Xin;WU Nan;WANG Yue(Jiangsu Cancer Hospital&Jiangsu Institution of Cancer Research&the Affiliated Cancer Hospital of Nanjing Medical University,Nanjing,Jiangsu 210009,China;Nanjing Medical University,Nanjing,Jiangsu 210029,China)

机构地区：[1]江苏省肿瘤医院&江苏省肿瘤防治研究所&南京医科大学附属肿瘤医院,南京210009 [2]南京医科大学,南京210029

出　　处：《药学与临床研究》2021年第5期377-380,共4页Pharmaceutical and Clinical Research

摘　　要：本文在PubMed、中国知网、万方医学数据库中,对PD-1/PD-L1类药物引起骨髓抑制的个案报道进行系统检索,共得文献55篇。按照入选标准/剔除标准筛选纳入20篇(22例),其中男性14例(占63.6%).使用PD-1/PD-L1抑制剂1周期后发生骨髓抑制12例(占54.55%),17例为Ⅳ级反应(占77.3%),16例表现为血小板减少症(占72.73%),2例表现为全血细胞减少症(占9.09%)。为临床了解PD-1/PD-L1抑制剂引起骨髓抑制发生特点、制定监护计划及处理该类不良反应提供依据。PubMed, CNKI and Wan-fang medical databases were systematically searched for case reports of myelosuppression induced by PD-1/PD-L1 drugs. A total of 55 literatures were obtained and 20(22 cases) were included for quantitative analysis. Among them, 14 cases(63.6%) were male, 11 cases(50%) had myelosuppression after using PD-1/PD-L1 inhibitors for 1 cycle, 17 cases(77.3%) were grade Ⅳ reaction, 16 cases(72.73%) were thrombocytopenia, 2 cases(9.09%) were pancytopenia. We provided a basis for medical staff to understand the characteristics of bone marrow suppression induced by PD-1/PD-L1 drugs, as well as its monitoring and treatment.

关 键 词：PD-1/PD-L1 肿瘤 骨髓抑制 血小板减少 

分 类 号：R969.3[医药卫生—药理学]